NS-1738

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H9Cl2F3N2O2
Molecular Weight	365.135
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(Cl)C=C1NC(=O)NC2=CC(=CC=C2Cl)C(F)(F)F

InChI

InChIKey=OUDXRNQPVSMGDW-UHFFFAOYSA-N

InChI=1S/C14H9Cl2F3N2O2/c15-8-2-4-12(22)11(6-8)21-13(23)20-10-5-7(14(17,18)19)1-3-9(10)16/h1-6,22H,(H2,20,21,23)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17625074 | https://www.ncbi.nlm.nih.gov/pubmed/23079470

NS1738 (1-(5-chloro-2-hydroxy-phenyl)-3-(2-chloro- 5-trifluoromethyl-phenyl)-urea) is a positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor (nAChR). NS1738 is capable of producing cognitive enhancement in vivo. NS1738 significantly reduced thermal hyperalgesia in mice.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Neuronal acetylcholine receptor protein alpha-7 subunit 77 Target ID: CHEMBL2492 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27711412 \| https://www.ncbi.nlm.nih.gov/pubmed/17625074 \| https://www.ncbi.nlm.nih.gov/pubmed/18678621	Positive Allosteric Modulator 179		34.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23079470	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo.	2007 Oct	17625074
Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment.	2008 Nov	18678621
In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile.	2009 Jul	19389923
Comparative pharmacology and computational modelling yield insights into allosteric modulation of human alpha7 nicotinic acetylcholine receptors.	2009 Oct 1	19549506
Competitive binding at a nicotinic receptor transmembrane site of two α7-selective positive allosteric modulators with differing effects on agonist-evoked desensitization.	2011 Dec	21820451
Effects of α7 positive allosteric modulators in murine inflammatory and chronic neuropathic pain models.	2013 Feb	23079470
The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models.	2013 Jan	23115222
Presynaptic α7 nicotinic acetylcholine receptors enhance hippocampal mossy fiber glutamatergic transmission via PKA activation.	2014 Jan 1	24381273
Theoretical study of the binding profile of an allosteric modulator NS-1738 with a chimera structure of the α7 nicotinic acetylcholine receptor.	2016 Oct 12	27711412

Patents

Sample Use Guides

In Vivo Use Guide

Rodents: 10 or 30 mg/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

Coapplication of NS1738 (5 μm) and nicotine (10 μm) induced a significant increase in evoked excitatory postsynaptic current amplitude in the mouse hippocampal CA3 pyramidal neurons

Name

Type

Language

NS-1738

Common Name

English

NSC-213859

Code

English

UREA, N-(5-CHLORO-2-HYDROXYPHENYL)-N'-(2-CHLORO-5-(TRIFLUOROMETHYL)PHENYL)-

Systematic Name

English

Code System Code Type Description

CAS

501684-93-1